M. Mackenzie

发表

Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC).

C. Garrett, T. Reid, J. Hecht, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.

D. Mahadevan, C. Deng, O. O’Connor, 2014 .